Atossa Therapeutics ATOS 深 沪
等待开盘 11-07 09:30:00 美东时间
2.16
+0.140
+6.93%
华盛通- 最 高2.1899
- 今 开1.99
- 成交量 2.47万股
- 最 低 1.99
- 昨 收 2.02
- 总市值 2155.53万
- 52周最高 14.85
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 1.70
- 委 比 -43.34%
- 总股本 997.93万
- 历史最高 33480.00
- 量 比 0.70
- 振 幅 9.90%
- 历史最低 1.70
- 每 手 1
- 风险率 3.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Atossa Genetics Inc收涨5.99%，成交额15.24万美元
11月3日，Atossa Genetics Inc（ATOS）收涨5.99%，报2.3美元，成交额15.24万美元，市值2295.2万美元。 行情数据 • 开盘...
11-03 08:42
Atossa Genetics Inc收跌4.41%，成交额20.93万美元
10月24日，Atossa Genetics Inc（ATOS）收跌4.41%，报2.6美元，成交额20.93万美元，市值2594.57万美元。 行情数据 •...
10-24 07:44
Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19
Under the terms of the Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, each share of Atossa common stock outstanding at the close of business on October 19, 2026 will receive, and have attached, one CVR. Each share issued after the record d...
10-19 20:10
Atossa Genetics Inc收涨9.81%，成交额28.78万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:44
Atossa Therapeutics Inks Stapled Contingent Value Rights Agreement With VStock Transfer; Atossa Declares Dividend Of One Stapled CVR For Each Share Of Atossa Common Stock
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that it has entered into a definitive Stapled Contingent Value Rights Agreement (the...
10-09 20:03
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.
10-01 17:19
Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share from the same period last year.
08-07 21:30
Atossa Therapeutics Announces npj Breast Cancer Publication Highlighting Novel Endoxifen-Based Compounds In ESR1-Mutant Breast Cancer Models
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib SEATTLE, July 28, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), ...
07-28 20:35
Atossa公布罕见病McCune-Albright综合征新数据
Atossa Therapeutics（纳斯达克代码：ATOS）在近日举行的美国癌症研究协会（AACR）罕见癌症特别会议上，以壁报形式公布了其在研药物（Z...
07-21 22:41
